Inhibition of mutant KRAS-driven overexpression of ARF6 and MYC by an eIF4A inhibitor drug improves the effects of anti-PD-1 immunotherapy for pancreatic cancer

Documenti analoghi

• High expression of AMAP1, an ARF6 effector, is associated with elevated levels of PD-L1 and fibrosis of pancreatic cancer
  di: Tsutaho, Akio, et al.
  Pubblicazione: (2020)
• ARF6 and AMAP1 are major targets of KRAS and TP53 mutations to promote invasion, PD-L1 dynamics, and immune evasion of pancreatic cancer
  di: Hashimoto, Shigeru, et al.
  Pubblicazione: (2019)
• Arf6 and its ZEB1-EPB41L5 mesenchymal axis are required for both mesenchymal- and amoeboid-type invasion of cancer cells
  di: Handa, Haruka, et al.
  Pubblicazione: (2017)
• Tumor responsiveness to statins requires overexpression of the ARF6 pathway
  di: Sabe, Hisataka, et al.
  Pubblicazione: (2016)
• Frequent overexpression of AMAP1, an Arf6 effector in cell invasion, is characteristic of the MMTV-PyMT rather than the MMTV-Neu human breast cancer model
  di: Otsuka, Yutaro, et al.
  Pubblicazione: (2018)